Skip to content

Study · Observational study · n = 11 · 2024

4 results

Difelikefalin and treatment of severe pruritus associated with chronic kidney disease Real-life retrospective study in a dialysis center

Brasme R, Cartery C, Goubet M, Hennino MF, Maisonneuve N

Nephrologie & therapeutique14 Jun 2024Cited by 2 (Europe PMC)

PMID39917796 (opens in a new tab)DOI10.1684/ndt.2024.78 (opens in a new tab)PepBankPUB-39917796
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanObservational studyEfficacy outcome

    In haemodialysis patients receiving difelikefalin, WI-NRS changed by -5.1 (2.9) after median follow-up of 9.0 months.

    In plain wordsDifelikefalin treatment was linked to lower itch scores than at baseline.

    Peptide
    Difelikefalin
    Outcome
    DecreaseWI-NRS change
    Study

    n = 11

    Analysis
    Primary
    Outcome group
    Skin and hair · Skin and wound
    Studied dose
    Dose not stated · median follow-up 9.0 monthsAs given in this study (human).

    Measurements

    Mean change in WI-NRS score from baseline
    −5.1 points
    11 patients, last assessment, median follow-up 9.0 months
    SD of mean WI-NRS change
    2.9 points
    11 patients, last assessment, median follow-up 9.0 months

    Source sentences

    Summary
    At last assessment after a median follow-up of 9.0 months, the mean change of WI-NRS score was -5.1 (2.9) and 82% of patients had a decrease ≥ 3 points.
    2 context sentences
    Summary · context
    This was a retrospective, single-center, real-life study in hemodialysis patients with CKD-aP treated with difelikefalin.
    Summary · context
    Adult patients were included if they had been on hemodialysis for at least 3 months and were suffering from moderate to severe CKD-aP (objectified by the WI-NRS score) for which difelikefalin had been prescribed.
  2. 02HumanObservational studyEfficacy outcome

    In haemodialysis patients receiving difelikefalin, 82% had a WI-NRS decrease of ≥3 points.

    In plain wordsDifelikefalin treatment was linked to an itch score decrease of ≥3 points from baseline in 82% of patients.

    Peptide
    Difelikefalin
    Outcome
    Decrease≥3-point WI-NRS decrease
    Study

    n = 11

    Outcome group
    Skin and hair · Skin and wound
    Studied dose
    Dose not stated · median follow-up 9.0 monthsAs given in this study (human).

    Measurements

    Patients with WI-NRS decrease >=3 points
    82%
    last assessment, median follow-up 9.0 months

    Source sentences

    Summary
    At last assessment after a median follow-up of 9.0 months, the mean change of WI-NRS score was -5.1 (2.9) and 82% of patients had a decrease ≥ 3 points.
    2 context sentences
    Summary · context
    This was a retrospective, single-center, real-life study in hemodialysis patients with CKD-aP treated with difelikefalin.
    Summary · context
    Adult patients were included if they had been on hemodialysis for at least 3 months and were suffering from moderate to severe CKD-aP (objectified by the WI-NRS score) for which difelikefalin had been prescribed.
  3. 03HumanObservational studySafety outcome

    In haemodialysis patients receiving difelikefalin, 4 reported mild to moderate adverse reactions.

    In plain wordsFour difelikefalin recipients reported mild to moderate adverse reactions.

    Peptide
    Difelikefalin
    Outcome
    Not applicableMild to moderate adverse reactions
    Study

    n = 11

    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated · median follow-up 9.0 monthsAs given in this study (human).

    Measurements

    Patients with mild to moderate adverse reactions
    4 patients
    11 patients receiving difelikefalin

    Source sentences

    Summary
    Mild to moderate adverse reactions to difelikefalin were reported in 4 patients, all of whom recovered without sequelae.
    2 context sentences
    Summary · context
    This was a retrospective, single-center, real-life study in hemodialysis patients with CKD-aP treated with difelikefalin.
    Summary · context
    Adult patients were included if they had been on hemodialysis for at least 3 months and were suffering from moderate to severe CKD-aP (objectified by the WI-NRS score) for which difelikefalin had been prescribed.
  4. 04HumanObservational studySafety outcome

    All 4 haemodialysis patients with adverse reactions to difelikefalin recovered without sequelae.

    In plain wordsAll patients with difelikefalin adverse reactions recovered without lasting effects.

    Peptide
    Difelikefalin
    Outcome
    Not applicableRecovery from adverse reactions
    Study

    n = 4

    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated · median follow-up 9.0 monthsAs given in this study (human).

    Measurements

    Patients with adverse reactions who recovered without sequelae
    4 patients
    patients with mild to moderate adverse reactions

    Source sentences

    Summary
    Mild to moderate adverse reactions to difelikefalin were reported in 4 patients, all of whom recovered without sequelae.
    2 context sentences
    Summary · context
    This was a retrospective, single-center, real-life study in hemodialysis patients with CKD-aP treated with difelikefalin.
    Summary · context
    Adult patients were included if they had been on hemodialysis for at least 3 months and were suffering from moderate to severe CKD-aP (objectified by the WI-NRS score) for which difelikefalin had been prescribed.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.